Try our beta test site

Efficacy of Selective Laser Trabeculoplasty in Patients Under Treatment With Topical Prostaglandines

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by University of Zurich.
Recruitment status was:  Enrolling by invitation
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01467440
First received: November 3, 2011
Last updated: January 5, 2015
Last verified: December 2014
  Purpose

Retrospective analysis of efficacy of selective laser trabeculoplasty in patients under treatment with topical prostaglandins compared to patients without topical prostaglandins is performed.

Inclusion criterion are patients with glaucoma or ocular hypertension, who underwent treatment with selective laser trabeculoplasty due to insufficient control of intraocular pressure during their routine treatment at the University Hospital Zurich / Division of Ophthalmology.


Condition Intervention Phase
Glaucoma
Ocular Hypertension
Device: Selective Laser Trabeculoplasty
Phase 4

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • IOP [ Time Frame: t0 ]

Estimated Enrollment: 200
Study Start Date: November 2011
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
PGA
Patients under glaucoma treatment with prostaglandines
Device: Selective Laser Trabeculoplasty
trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Other Name: SLT-Laser, Tango Laser, Ellex Medical Pty. Ltd., 82 Gilbert Street, Adelaide, SA 5000 Australia
NON-PGA
Patient not recieving prostaglandines to treat their glaucoma
Device: Selective Laser Trabeculoplasty
trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Other Name: SLT-Laser, Tango Laser, Ellex Medical Pty. Ltd., 82 Gilbert Street, Adelaide, SA 5000 Australia

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
glaucoma patients
Criteria

Inclusion criteria:

  • Patients with ocular hypertension or glaucoma who underwent selective laser trabeculoplasty due to insufficient control of intraocular pressure despite maximum tolerated topical treatment.

Exclusion criteria:

  • Optic neuropathy other than glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01467440

Locations
Switzerland
University Hospital Zurich, Ophthalmic Clinic
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Investigators
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
Principal Investigator: Jens Funk, Professor, MD University Hospital Zurich, Ophtalmic Clinic
  More Information

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01467440     History of Changes
Other Study ID Numbers: SLT_PG_2011 
Study First Received: November 3, 2011
Last Updated: January 5, 2015

Keywords provided by University of Zurich:
Glaucoma and Ocular Hypertension

Additional relevant MeSH terms:
Hypertension
Glaucoma
Ocular Hypertension
Vascular Diseases
Cardiovascular Diseases
Eye Diseases

ClinicalTrials.gov processed this record on February 24, 2017